Garber A J
J Clin Invest. 1978 Sep;62(3):623-32. doi: 10.1172/JCI109169.
The kinetics and factors regulating alanine and glutamine formation and release were investigated in skeletal muscle preparations from control and experimentally uremic rats. These preparations maintained phosphocreatine and ATP levels in vitro which closely approximated levels found in vivo. Alanine and glutamine release from uremic muscle were increased 45.8 and 36.0%, respectively, but tissue levels were unaltered. The increased release of alanine by uremic muscle was not accounted for by decreased rates of medium alanine reutilization via oxidation to CO(2) or incorporation into muscle protein. The maximal capacity of added amino acids such as aspartate, cysteine, leucine, and valine to stimulate net alanine and glutamine formation was the same in uremic and control muscle. Epitrochlearis preparations were partially labeled in vivo with [guanido-(14)C]-arginine. On incubation, preparations from uremic animals showed a 54.6% increase in the rate of loss of (14)C-label in acid precipitable protein. Correspondingly, these same uremic preparations showed a 62.7% increase in (14)C-label appearance in the acid-soluble fraction of muscle and in the incubation media. Insulin decreased alanine and glutamine release to an extent threefold greater in uremic than in control preparations, and increased muscle glucose uptake approximately threefold in all preparations. Although basal rates of [4,5-(3)H]leucine incorporation into protein were decreased 25% in uremic muscles as compared with control muscles, insulin stimulated [(3)H]leucine incorporation nearly equally in both preparations. These data demonstrate increased alanine and glutamine production and release from skeletal muscle of chronically uremic rats. This increase appears to derive in part from an enhancement of net protein degradation which could be caused by an acceleration in the breakdown of one or more groups of muscle proteins, or by an inhibition of protein synthesis, or by both processes. The increased alanine and glutamine formation and release in uremia appears not to result from an insensitivity to insulin action. The implications of these findings for an understanding of the abnormal carbohydrate metabolism of uremia are discussed.
在对照大鼠和实验性尿毒症大鼠的骨骼肌标本中,研究了调节丙氨酸和谷氨酰胺生成及释放的动力学和相关因素。这些标本在体外维持的磷酸肌酸和三磷酸腺苷(ATP)水平与体内水平非常接近。尿毒症肌肉中丙氨酸和谷氨酰胺的释放分别增加了45.8%和36.0%,但组织内水平未改变。尿毒症肌肉中丙氨酸释放增加并非由于通过氧化生成二氧化碳或掺入肌肉蛋白而导致的培养基中丙氨酸再利用速率降低。添加的氨基酸如天冬氨酸、半胱氨酸、亮氨酸和缬氨酸刺激净丙氨酸和谷氨酰胺生成的最大能力在尿毒症肌肉和对照肌肉中相同。在体内用[胍基 - (14)C] - 精氨酸对肱三头肌标本进行部分标记。孵育时,尿毒症动物的标本显示酸性可沉淀蛋白中(14)C标记的损失率增加了54.6%。相应地,这些相同的尿毒症标本在肌肉和孵育培养基的酸溶性部分中(14)C标记的出现增加了62.7%。胰岛素降低尿毒症标本中丙氨酸和谷氨酰胺释放的程度是对照标本的三倍,并且在所有标本中使肌肉葡萄糖摄取增加约三倍。尽管与对照肌肉相比,尿毒症肌肉中[4,5 - (3)H]亮氨酸掺入蛋白的基础速率降低了25%,但胰岛素在两种标本中刺激[(3)H]亮氨酸掺入的程度几乎相同。这些数据表明,慢性尿毒症大鼠骨骼肌中丙氨酸和谷氨酰胺的生成及释放增加。这种增加似乎部分源于净蛋白降解的增强,这可能是由于一组或多组肌肉蛋白分解加速、蛋白合成受抑制或两者共同作用所致。尿毒症中丙氨酸和谷氨酰胺生成及释放的增加似乎并非源于对胰岛素作用不敏感。讨论了这些发现对理解尿毒症异常碳水化合物代谢的意义。